RU2007123607A - Противоопухолевые комбинации, содержащие агент, ингибирующий vegf, и 5fu или одно из его производных - Google Patents
Противоопухолевые комбинации, содержащие агент, ингибирующий vegf, и 5fu или одно из его производных Download PDFInfo
- Publication number
- RU2007123607A RU2007123607A RU2007123607/15A RU2007123607A RU2007123607A RU 2007123607 A RU2007123607 A RU 2007123607A RU 2007123607/15 A RU2007123607/15 A RU 2007123607/15A RU 2007123607 A RU2007123607 A RU 2007123607A RU 2007123607 A RU2007123607 A RU 2007123607A
- Authority
- RU
- Russia
- Prior art keywords
- fluorouracil
- vegf
- treatment
- combinations
- combinations containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (8)
1. Комбинации, содержащие ингибитор VEGF и по меньшей мере 5-фторурацил или производное 5-фторопиримидина, пригодное для лечения новообразований.
2. Комбинации, содержащие ингибитор VEGF и 5-фторурацил, или капецитабин, или гемцитабин.
3.Комбинации по п.2, содержащие ингибитор VEGF и фторурацил.
4. Комбинации по п.3, содержащие ингибитор VEGF Trap и 5-фторурацил.
5. Комбинации по пп.1-4, отличающиеся тем, что они дополнительно содержат фолиновую кислоту.
6. Комбинации по п.4, отличающиеся тем, что они содержат от 2 до 80 вес.% VEGF Trap.
7. Продукты, содержащие ингибитор VEGF и по меньшей мере одно терапевтически пригодное вещество, такое, как определено по любому из пп.1-5, для лечения новообразований в качестве комбинированного препарата для одновременного, отдельного или распределенного во времени применения при лечении рака.
8. Комбинации, содержащие ингибитор VEGF и по меньшей мере 5-фторурацил или производное 5-фторопиримидина и фолиновую кислоту за исключением любого другого химиотоксичного производного, обладающие синергетическим терапевтическим действием при лечении новообразований.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0412870A FR2878749B1 (fr) | 2004-12-03 | 2004-12-03 | Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives |
| FR0412870 | 2004-12-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2007123607A true RU2007123607A (ru) | 2009-01-10 |
| RU2384344C2 RU2384344C2 (ru) | 2010-03-20 |
Family
ID=34954452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007123607/15A RU2384344C2 (ru) | 2004-12-03 | 2005-12-02 | Противоопухолевые комбинации, содержащие агент, ингибирующий vegf и 5fu или одно из его производных |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20060178305A1 (ru) |
| EP (1) | EP1824504B1 (ru) |
| JP (1) | JP4980236B2 (ru) |
| KR (1) | KR101313404B1 (ru) |
| CN (1) | CN101068564B (ru) |
| AT (1) | ATE426409T1 (ru) |
| AU (1) | AU2005311191C1 (ru) |
| BR (1) | BRPI0518700B8 (ru) |
| CA (1) | CA2586735C (ru) |
| CY (3) | CY1109181T1 (ru) |
| DE (1) | DE602005013568D1 (ru) |
| DK (1) | DK1824504T3 (ru) |
| ES (1) | ES2324233T3 (ru) |
| FR (1) | FR2878749B1 (ru) |
| HK (1) | HK1114769A1 (ru) |
| HR (1) | HRP20090336T1 (ru) |
| IL (1) | IL183481A (ru) |
| LU (2) | LU92202I2 (ru) |
| ME (1) | ME01706B (ru) |
| MX (1) | MX2007006607A (ru) |
| PL (1) | PL1824504T3 (ru) |
| PT (1) | PT1824504E (ru) |
| RS (1) | RS50769B (ru) |
| RU (1) | RU2384344C2 (ru) |
| SI (1) | SI1824504T1 (ru) |
| WO (1) | WO2006059012A1 (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2918279B1 (fr) * | 2007-07-05 | 2010-10-22 | Aventis Pharma Sa | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan |
| JO3283B1 (ar) * | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| ES2732925T3 (es) | 2014-07-18 | 2019-11-26 | Sanofi Sa | Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer |
| RU2744860C2 (ru) | 2015-12-30 | 2021-03-16 | Кодиак Сайенсиз Инк. | Антитела и их конъюгаты |
| EP3246029A1 (en) * | 2016-05-19 | 2017-11-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer |
| EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | METHOD FOR TREATING AN EYE DISORDER |
| CN115197948A (zh) * | 2021-04-13 | 2022-10-18 | 江苏康缘瑞翱生物医药科技有限公司 | 一种重组新城疫病毒rNDV-VEGF-Trap、其基因组、制备方法及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60019415T2 (de) * | 1999-06-08 | 2006-03-09 | Regeneron Pharmaceuticals, Inc. | Modifizierte chimärische polypeptide mit verbesserten pharmakokynetischen eigenschaften |
| US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| AR046510A1 (es) * | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
-
2004
- 2004-12-03 FR FR0412870A patent/FR2878749B1/fr active Active
-
2005
- 2005-12-02 BR BRPI0518700A patent/BRPI0518700B8/pt active IP Right Grant
- 2005-12-02 AT AT05824581T patent/ATE426409T1/de active
- 2005-12-02 DK DK05824581T patent/DK1824504T3/da active
- 2005-12-02 ES ES05824581T patent/ES2324233T3/es active Active
- 2005-12-02 PL PL05824581T patent/PL1824504T3/pl unknown
- 2005-12-02 EP EP05824581A patent/EP1824504B1/fr active Active
- 2005-12-02 AU AU2005311191A patent/AU2005311191C1/en active Active
- 2005-12-02 SI SI200530696T patent/SI1824504T1/sl unknown
- 2005-12-02 DE DE602005013568T patent/DE602005013568D1/de active Active
- 2005-12-02 ME MEP-2009-272A patent/ME01706B/me unknown
- 2005-12-02 KR KR1020077012431A patent/KR101313404B1/ko active IP Right Grant
- 2005-12-02 RU RU2007123607/15A patent/RU2384344C2/ru active Protection Beyond IP Right Term
- 2005-12-02 JP JP2007543885A patent/JP4980236B2/ja active Active
- 2005-12-02 CN CN2005800416406A patent/CN101068564B/zh active Active
- 2005-12-02 RS RSP-2009/0272A patent/RS50769B/sr unknown
- 2005-12-02 MX MX2007006607A patent/MX2007006607A/es active IP Right Grant
- 2005-12-02 US US11/293,761 patent/US20060178305A1/en not_active Abandoned
- 2005-12-02 WO PCT/FR2005/003005 patent/WO2006059012A1/fr active Application Filing
- 2005-12-02 CA CA2586735A patent/CA2586735C/fr active Active
- 2005-12-02 PT PT05824581T patent/PT1824504E/pt unknown
-
2007
- 2007-05-28 IL IL183481A patent/IL183481A/en active IP Right Grant
-
2008
- 2008-04-28 HK HK08104697.0A patent/HK1114769A1/xx unknown
-
2009
- 2009-06-12 HR HR20090336T patent/HRP20090336T1/xx unknown
- 2009-06-25 CY CY20091100671T patent/CY1109181T1/el unknown
- 2009-07-24 US US12/508,834 patent/US8388963B2/en active Active
-
2013
- 2013-03-04 US US13/783,919 patent/US20130184205A1/en not_active Abandoned
- 2013-05-13 CY CY2013017C patent/CY2013017I1/el unknown
- 2013-05-13 CY CY2013018C patent/CY2013018I1/el unknown
- 2013-05-15 LU LU92202C patent/LU92202I2/fr unknown
- 2013-05-15 LU LU92203C patent/LU92203I2/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007123607A (ru) | Противоопухолевые комбинации, содержащие агент, ингибирующий vegf, и 5fu или одно из его производных | |
| EA201890888A1 (ru) | Новые спиро[3h-индол-3,2'-пирролидин]-2(1h)-оновые соединения и производные в качестве ингибиторов mdm2-p53 | |
| EA202191801A1 (ru) | Гетероциклические ингибиторы mat2a и способы применения для лечения рака | |
| UY27875A1 (es) | Prodrogas 2 ' y 3 ' de nucleósidos modificados para tratar flaviviridae | |
| CL2019003309A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
| CL2019002745A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
| CY1107253T1 (el) | Παραγωγα της 5-αμινο-2,4,7-τριοξο-3,4,7,8-τετραϋδρο-2h-πυριδο[2,3-d] πυριμιδινης και παρομοιες ενωσεις για την αγωγη του καρκινου | |
| PT1404347E (pt) | Nucleosidos 4'-substituidos para o tratamento de doencas mediadas pelo virus da hepatite c | |
| EA202191800A1 (ru) | Азагетеробициклические ингибиторы мат2а и способы их применения для нацеливания на рак | |
| EA200500893A1 (ru) | Трициклические соединения, представляющие собой ингибиторы протеинкиназ, для увеличения эффективности противоопухолевых агентов и лучевой терапии | |
| EA200800178A1 (ru) | Ингибиторы вируса гепатита с (hcv) | |
| CY1113323T1 (el) | Ενωσεις τετραϋδροφουρο[3,4-d]διοξολανιου για χρηση στη θεραπεια ιικων μολυνσεων και καρκινου | |
| EA200701808A1 (ru) | Производные тетрагидроиндолона и тетрагидроиндазолона | |
| AR028810A1 (es) | Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion | |
| CL2011000124A1 (es) | Compuestos derivados de 3-aril-4-heterociclil-pirazoles, inhibidores de proteina quinasa b-raf; metodo de inhibicion in vitro de la proteina quinasa b-raf; composicion farmaceutica; producto de combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| CL2011000589A1 (es) | Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer. | |
| DE60140814D1 (de) | N-phenyl-2-pyrimidine-amine derivatives | |
| WO2008100447A3 (en) | Nucleoside analogs for antiviral treatment | |
| CL2019002744A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
| BRPI0618552B8 (pt) | compostos derivados de pirimidina ligados ao oxigênio,composição farmacêutica que inclui os ditos compostos,método de síntese dos compostos e usos terapêuticos dos mesmos | |
| CR20220675A (es) | Análogos de nucleósido de 1´- ciano y usos de los mismos | |
| CL2019003294A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
| DE602008003404D1 (de) | 5,6,7,8-tetrahydropteridin-derivate als hsp90-hemmer | |
| HRP20110432T1 (hr) | Antitumorske kombinacije koje sadrže sredstvo za inhibiranje vegf i irinotekan | |
| MX2022001789A (es) | Derivados de 2-hidroxicicloalcan-1-carbamoilo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ND4A | Extension of patent duration |
Free format text: CLAIMS: 1-4 Extension date: 20290715 |